RxDoctor Payments Data

Ki Hong Ho, MD

Otolaryngology · San Francisco, CANPI 1215131883

Payments from drug & device makers

$903in general payments, 2019–2025

Across 28 payments — averaging $32.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$436
  • Amgen$160
  • Stryker$103
  • Optinose US, Inc.$100
  • Intersect ENT, Inc.$61
  • Johnson & Johnson$30
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$903100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$903 in reported general payments places this provider in the 45th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California

Medicare billing

Part B allowed, 2024
$198,996
Medicare patients
609
Services billed
1,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate18$10,479
Azelastine Hcl229$4,865
Ofloxacin161$4,675
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth47$3,872
Fluticasone Propionate376$3,331
Fluocinonide146$3,084
Ipratropium Bromide84$2,201
Triamcinolone Acetonide114$2,015
Fluocinolone Acetonide Oil32$1,217
Omeprazole117$1,144
Acetic Acid37$677
Clotrimazole22$607
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav94$563
Chlorhexidine Gluconate79$456
Famotidine17$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$100$10,47918 claims
Medline Industries LPAcetic Acid$14$67737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,021 otolaryngology providers in California.

Other otolaryngology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →